Vutrisiran
Hereditary Transthyretin Amyloidosis
Phase 3Active
Key Facts
Indication
Hereditary Transthyretin Amyloidosis
Phase
Phase 3
Status
Active
Company
About Alnylam Pharmaceuticals
Founded in 2002, Alnylam Pharmaceuticals is a leading biopharmaceutical company that pioneered the RNAi therapeutics revolution. The company leverages RNA interference technology to selectively silence genes that cause or contribute to disease, offering a fundamentally different approach to treating genetic disorders. With multiple approved therapies and a strong pipeline focused on rare diseases, Alnylam has established itself as the definitive leader in RNAi therapeutics with global reach and operations.
View full company profileTherapeutic Areas
Other Hereditary Transthyretin Amyloidosis Drugs
| Drug | Company | Phase |
|---|---|---|
| Patisiran (ONPATTRO) | Alnylam Pharmaceuticals | Approved |